| scholarly article | Q13442814 |
| P50 | author | Kevin A Peterson | Q58815657 |
| P2093 | author name string | Jack L. Leahy | |
| Doron Schneider | |||
| Irl B. Hirsch | |||
| P2860 | cites work | Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin | Q22250892 |
| Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q24642503 | ||
| One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial | Q24656644 | ||
| Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance | Q28186874 | ||
| Glucagon-like peptide-1 receptor is involved in learning and neuroprotection | Q28202403 | ||
| The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes | Q28273497 | ||
| Relationships Between Fasting Plasma Glucose Levels and Insulin Secretion During Intravenous Glucose Tolerance Tests | Q51671449 | ||
| Type 2 diabetes-a matter of beta-cell life and death? | Q53873519 | ||
| Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. | Q53886146 | ||
| Selective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea | Q57214866 | ||
| Quality Improvement | Q57277707 | ||
| Induction of Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients by Transient Intensive Insulin Treatment | Q57499758 | ||
| UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years | Q58678919 | ||
| Compensatory Adaption to Partial Pancreatectomy in the Rat* | Q60192453 | ||
| Reduced incretin effect in type 2 (non-insulin-dependent) diabetes | Q68865252 | ||
| The role of patient, physician and systemic factors in the management of type 2 diabetes mellitus | Q74444582 | ||
| American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus | Q80572896 | ||
| Pathogenesis of type 2 diabetes mellitus | Q81798256 | ||
| A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans | Q48664995 | ||
| Thiazolidinediones improve beta-cell function in type 2 diabetic patients. | Q51485541 | ||
| Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. | Q51568023 | ||
| Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. | Q51571637 | ||
| Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. | Q51598262 | ||
| Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. | Q51601217 | ||
| Pancreatic beta-cell growth and survival in the onset of type 2 diabetes: a role for protein kinase B in the Akt? | Q28273511 | ||
| A genome-wide association study identifies novel risk loci for type 2 diabetes | Q28287727 | ||
| Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats | Q28578709 | ||
| Structure-Function of the Glucagon Receptor Family of G Protein-Coupled Receptors: The Glucagon, GIP, GLP-1, and GLP-2 Receptors | Q29400367 | ||
| Diet, lifestyle, and the risk of type 2 diabetes mellitus in women | Q29614196 | ||
| Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes | Q29619192 | ||
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
| How can primary care cross the quality chasm? | Q30438751 | ||
| Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year | Q33220335 | ||
| Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial | Q33425402 | ||
| The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance | Q33705046 | ||
| The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus | Q33853759 | ||
| Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial | Q33999757 | ||
| Beta-cell adaptation and decompensation during the progression of diabetes. | Q34197338 | ||
| Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes | Q34424907 | ||
| The in vivo regulation of pulsatile insulin secretion | Q34531310 | ||
| Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial | Q34572519 | ||
| Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis | Q34648377 | ||
| Pancreatic beta-cell growth and survival--a role in obesity-linked type 2 diabetes? | Q34750166 | ||
| Diabetes management in the primary care setting: summary | Q34997002 | ||
| Enhancing Incretin Action for the Treatment of Type 2 Diabetes | Q35545683 | ||
| Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications | Q35651511 | ||
| The evolving diabetes burden in the United States | Q35789756 | ||
| Five stages of evolving beta-cell dysfunction during progression to diabetes | Q35961960 | ||
| Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion | Q35981591 | ||
| GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. | Q36075983 | ||
| Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta-regression analysis | Q36547032 | ||
| beta-cell failure in diabetes and preservation by clinical treatment | Q36757992 | ||
| The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond | Q36945116 | ||
| beta-cell function and anti-diabetic pharmacotherapy | Q36947018 | ||
| Improving Diabetes Care in Practice: findings from the TRANSLATE trial. | Q36975614 | ||
| Replication study of candidate genes associated with type 2 diabetes based on genome-wide screening | Q37066951 | ||
| Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins | Q37091579 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance | Q37240093 | ||
| How doctors choose medications to treat type 2 diabetes: a national survey of specialists and academic generalists. | Q37312905 | ||
| Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans | Q37377728 | ||
| Functional pancreatic beta-cell mass: involvement in type 2 diabetes and therapeutic intervention | Q37404211 | ||
| Projecting the future diabetes population size and related costs for the U.S. | Q37437118 | ||
| The scientific evidence: vildagliptin and the benefits of islet enhancement | Q37455197 | ||
| Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach | Q38723548 | ||
| Is glycemic control improving in U.S. adults? | Q40164421 | ||
| Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects* | Q40329405 | ||
| The burden of treatment failure in type 2 diabetes | Q40500624 | ||
| Determinants of glucose toxicity and its reversibility in the pancreatic islet beta-cell line, HIT-T15. | Q40846007 | ||
| Prolactin (in vitro) decreases the glucose stimulation threshold, enhances insulin secretion, and increases dye coupling among islet B cells | Q41430817 | ||
| Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance | Q41432167 | ||
| Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. | Q42446467 | ||
| Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. | Q42520650 | ||
| Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. | Q42524942 | ||
| Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. | Q42525265 | ||
| Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes | Q43194107 | ||
| How our current medical care system fails people with diabetes: lack of timely, appropriate clinical decisions | Q43196276 | ||
| A model-based method for assessing insulin sensitivity from the oral glucose tolerance test | Q43566553 | ||
| Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death | Q43596005 | ||
| Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes | Q43867550 | ||
| Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). | Q43869405 | ||
| Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans | Q43884231 | ||
| Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study | Q43919658 | ||
| Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women | Q44114894 | ||
| Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1. | Q44234328 | ||
| Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets | Q44320631 | ||
| Deteriorating beta-cell function in type 2 diabetes: a long-term model | Q44372257 | ||
| Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. | Q44442300 | ||
| The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose | Q44493423 | ||
| Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium | Q44512663 | ||
| Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion | Q44774818 | ||
| One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. | Q44865459 | ||
| Short-term intensive insulin therapy in newly diagnosed type 2 diabetes | Q44865579 | ||
| Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes | Q45124446 | ||
| Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function | Q45124452 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes | Q45124469 | ||
| Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism | Q45176382 | ||
| Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury | Q45199143 | ||
| Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes | Q45285687 | ||
| Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. | Q46457151 | ||
| Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes | Q46484235 | ||
| Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. | Q46576386 | ||
| Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes | Q46689486 | ||
| Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test | Q46708958 | ||
| Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure | Q46817496 | ||
| Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey | Q46966712 | ||
| Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas | Q47234077 | ||
| Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes | Q47296454 | ||
| Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes | Q47333592 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| cell function | Q95674809 | ||
| P304 | page(s) | 4206-4216 | |
| P577 | publication date | 2010-08-25 | |
| P1433 | published in | The Journal of Clinical Endocrinology and Metabolism | Q3186902 |
| P1476 | title | Targeting beta-cell function early in the course of therapy for type 2 diabetes mellitus | |
| Targeting β-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus | |||
| P478 | volume | 95 |
| Q57147350 | Acute phase ketosis-prone atypical diabetes is associated with a pro-inflammatory profile: a case-control study in a sub-Saharan African population |
| Q30279270 | An Islet-Targeted Genome-Wide Association Scan Identifies Novel Genes Implicated in Cytokine-Mediated Islet Stress in Type 2 Diabetes |
| Q87406656 | Anti-TCR therapy combined with fingolimod for reversal of diabetic hyperglycemia by β cell regeneration in the LEW.1AR1-iddm rat model of type 1 diabetes |
| Q58032898 | Botanical, Pharmacological, Phytochemical, and Toxicological Aspects of the Antidiabetic Plant Bidens pilosa L |
| Q38086802 | Can C-peptide mediated anti-inflammatory effects retard the development of microvascular complications of type 1 diabetes? |
| Q38129446 | Choice of early treatment regimen and impact on β-cell preservation in type 2 diabetes |
| Q30410968 | Circulating levels of IL-1B+IL-6 cause ER stress and dysfunction in islets from prediabetic male mice |
| Q34142893 | Determinants of successful glycemic control among participants in the BARI 2D trial: a post-hoc analysis |
| Q37102832 | Diabetes prevention: can insulin secretagogues do the job? |
| Q35027017 | Diet is critical for prolonged glycemic control after short-term insulin treatment in high-fat diet-induced type 2 diabetic male mice |
| Q89525746 | Different β-cell secretory phenotype in non-obese compared to obese early type 2 diabetes |
| Q36367159 | Dopamine synthesis and D3 receptor activation in pancreatic β-cells regulates insulin secretion and intracellular [Ca(2+)] oscillations |
| Q35125338 | Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial |
| Q34347884 | Emerging gliptins for type 2 diabetes |
| Q35774014 | FTY720 normalizes hyperglycemia by stimulating β-cell in vivo regeneration in db/db mice through regulation of cyclin D3 and p57(KIP2). |
| Q57821472 | Formula Inhibits Pancreatic Cell Apoptosis in Type 2 Diabetes Mellitus via MEK-ERK-Caspase-3 Signaling Pathway |
| Q36801780 | Herbal therapies for type 2 diabetes mellitus: chemistry, biology, and potential application of selected plants and compounds |
| Q41689680 | Human beta cell mass and function in diabetes: Recent advances in knowledge and technologies to understand disease pathogenesis |
| Q34446705 | In vivo pancreatic β-cell-specific expression of antiaging gene Klotho: a novel approach for preserving β-cells in type 2 diabetes |
| Q40747617 | Incidence and correlated factors of beta cell failure in a 4-year follow-up of patients with type 2 diabetes: a longitudinal analysis of the BETADECLINE study. |
| Q36232791 | Insulin combined with Chinese medicine improves glycemic outcome through multiple pathways in patients with type 2 diabetes mellitus |
| Q30277210 | Islet Hypersensitivity to Glucose Is Associated With Disrupted Oscillations and Increased Impact of Proinflammatory Cytokines in Islets From Diabetes-Prone Male Mice |
| Q54263630 | Liraglutide protects pancreatic beta cells during an early intervention in Gato-Kakizaki rats. |
| Q41893915 | Loss of pulsatile insulin secretion: a factor in the pathogenesis of type 2 diabetes? |
| Q35550591 | Mitochondrial dysfunction and β-cell failure in type 2 diabetes mellitus |
| Q35221336 | Novel views on new-onset diabetes after transplantation: development, prevention and treatment. |
| Q46863028 | Overexpression of PPARγ specifically in pancreatic β-cells exacerbates obesity-induced glucose intolerance, reduces β-cell mass, and alters islet lipid metabolism in male mice |
| Q64988157 | Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling-dependent manner. |
| Q30708894 | Pancreatic β-Cell Adaptive Plasticity in Obesity Increases Insulin Production but Adversely Affects Secretory Function |
| Q38762877 | Periodontitis aggravated pancreatic β-cell dysfunction in diabetic mice through interleukin-12 regulation on Klotho |
| Q39111984 | Potent effects of the total saponins from Dioscorea nipponica Makino against streptozotocin-induced type 2 diabetes mellitus in rats |
| Q91618221 | Reducing Glucokinase Activity Restores Endogenous Pulsatility and Enhances Insulin Secretion in Islets From db/db Mice |
| Q37588072 | Sanqi panax notoginseng injection for angina pectoris |
| Q38246691 | Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps |
| Q51364005 | Species incompatibilities in the pig-to-macaque islet xenotransplant model affect transplant outcome: a comparison with allotransplantation. |
| Q36224740 | Suppression of ROS Production by Exendin-4 in PSC Attenuates the High Glucose-Induced Islet Fibrosis |
| Q29347032 | Suppression of the nuclear factor Eny2 increases insulin secretion in poorly functioning INS-1E insulinoma cells |
| Q38051409 | Sus1/ENY2: a multitasking protein in eukaryotic gene expression |
| Q38224544 | Targeting type 2 diabetes: lessons from a knockout model of insulin receptor substrate 2. |
| Q33585610 | Targeting β-cell functions in therapy for type 2 diabetes |
| Q41689708 | The dynamic plasticity of insulin production in β-cells. |
| Q37989176 | The link between polycystic ovary syndrome and both Type 1 and Type 2 diabetes mellitus: what do we know today? |
| Q26995759 | The role of peroxidation of mitochondrial membrane phospholipids in pancreatic β -cell failure |
| Q54395756 | Tungstate promotes β-cell survival in Irs2-/- mice. |
| Q48233504 | Type 2 diabetes: Does pancreatic fat really matter? |
| Q37217511 | Update on insulin therapy for type 2 diabetes |
| Q37110587 | Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and β-cell Function in type 2 diabetic patients |
| Q47876102 | β-Cell function in postmenopausal women with isolated post-challenge hyperglycemia. |
Search more.